Fourteen days instead of twenty-eight, and a new centre built for medicines that learn
What happened
On 14 October 2026, the UK's medicines regulator published a plan for the next four years. It is called the MHRA 2030 Strategy, and it is largely a plan about software. The MHRA is the body that decides whether a medicine or a medical device can be sold in the UK, and that watches for problems afterwards. Its new strategy sets out how it intends to handle two things that are changing fast: artificial intelligence, and medicines tailored to individual people. Several commitments are specific and measurable. The agency will cut the initial assessment of Phase 1 clinical trials from 28 days to 14. Phase 1 is the first time a new medicine is given to humans, usually to a small group, to check basic safety. It will offer a faster scientific advice option, reducing one route from 90 days to 45 days. Scientific advice is where a company asks the regulator, before running expensive studies, whether its plan is likely to be acceptable. It will set up an MHRA Centre for AI and Digital Health, to make clear what it expects from AI-driven devices and medicines. It will build an AI-enabled Clinical Trial Protocol Checker, so companies can test a trial design against the rules earlier. And it will publish an AI Medicines Development Action Plan in 2027. The MHRA also says it will use AI itself, to sift real-world data from hospitals and spot safety signals earlier, and it plans real-time surveillance with the Health Data Research Service. Lawrence Tallon, the MHRA's Chief Executive, said: "AI is transforming both regulated products and how organisations are run."
Why this matters
Most people will never read a regulator's strategy. But the speed of a regulator decides, quietly, how long you wait for a treatment. If a company has to wait 28 days for a first look at its Phase 1 trial, and 90 days for scientific advice, and then wait again, those delays stack up across a drug's whole life. Halving some of them does not get a medicine to a pharmacy shelf next year. Over a decade, it shifts the timetable. The AI side matters for a different reason. Software is now a medical device in its own right. A piece of software that reads a brain scan, flags a suspicious mammogram or interprets an EEG is regulated much like a physical machine. The awkward part is that traditional rules assume a product stays the same once approved. AI models do not always stay the same. They can be retrained and updated. That is the gap the new Centre for AI and Digital Health is meant to fill, with what the strategy describes as a modern, adaptive framework for AI as a medical device. There is a second, less obvious change. The MHRA says it will move away from animal models towards human-relevant methods such as organoids. Organoids are tiny clumps of human cells grown in a lab to behave a little like a real organ. That is a shift in how safety is tested at all, not just how fast.
What the evidence actually says
A strategy is a statement of intent. It is worth separating what has been decided from what has been promised. The MHRA's own release contains no statistics, no funding figures and no adoption data. There is no budget attached in the announcement, and no detail on how the agency will recruit the specialist staff that AI assessment needs. The firm dates are modest. The Women's Health Plan and a refreshed Patient and Public Involvement and Engagement Plan are promised for this year, 2026. The AI Medicines Development Action Plan is promised for 2027. The Centre for AI and Digital Health, the protocol checker and the adaptive AI device framework are commitments without published completion dates in the release. The faster timelines are targets, not results. Cutting Phase 1 assessment to 14 days is a goal; whether it is met will show up in future performance reporting, which the strategy says will be measured. Industry reaction was positive but pointed. Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, called the strategy "clear on speed, clear on standards and clear on how performance will be measured". That last phrase is the real test. Praise for measurement is praise for being held to it later. Dr Matt Westmore, Chief Executive of the Health Research Authority, pointed to "the largest overhaul of clinical trials legislation for a generation" delivered in the past 12 months, and said the HRA and MHRA will align their digital processes. The strategy also covers international routes, including expanded reliance and recognition arrangements with the US Food and Drug Administration, continued recognition of CE-marked devices, and the UK chairing the Access Consortium alongside Australia, Canada, Singapore and Switzerland.
Practical advice
This is a story about institutions, but there are a few things worth knowing as a patient. **Faster approval is not the same as faster access.** The MHRA decides whether a medicine can be sold. NICE decides whether the NHS should pay for it, and local prescribing lists decide what is routinely available where you live. All three steps matter. **Be sceptical of AI health apps that are not regulated devices.** Plenty of apps make health claims without being assessed by anyone. If an app claims to diagnose or screen for a condition, ask whether it is a registered medical device. Your GP or pharmacist can usually tell you whether a tool is one the NHS actually uses. **Report suspected side effects yourself.** The strategy puts weight on real-world safety data, and promises to simplify Yellow Card reporting. The Yellow Card scheme, at yellowcard.mhra.gov.uk, is open to patients, not only clinicians. Earlier signals come from more reports. **Consider taking part in a clinical trial if one is offered.** The strategy commits to increasing trial diversity, which matters because a medicine tested mainly on one group may not work identically in another. Be Part of Research, run by the NIHR, lists UK studies. **Do not read "personalised medicine" as "available now".** Treatments matched to an individual's genetics are real, but mostly in cancer and rare disease, and mostly in specialist centres.
What to know
The MHRA has published a strategy running to 2030, aimed squarely at AI and personalised medicines. The headline commitments are a cut in Phase 1 clinical trial initial assessment from 28 days to 14, a faster scientific advice route down from 90 days to 45, a new MHRA Centre for AI and Digital Health, an AI-enabled trial protocol checker, an AI Medicines Development Action Plan in 2027, and a move away from animal testing towards human-relevant methods such as organoids. These are targets rather than achievements. The announcement carries no statistics, no budget and few firm dates, and the AI device framework is described rather than published. The industry's welcome centred on the promise that performance will be measured, which is also where this strategy can be judged in a year or two. For patients, the useful points are smaller: a licence is not the same as NHS funding, unregulated AI health apps deserve caution, and Yellow Card reports from ordinary people are part of how the new real-world safety monitoring is supposed to work. Sources: Medicines and Healthcare products Regulatory Agency, "MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines", 14 October 2026, https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines; Medicines and Healthcare products Regulatory Agency homepage, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency; Medicines and Healthcare products Regulatory Agency, Yellow Card scheme, https://yellowcard.mhra.gov.uk This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Regulatory changes do not alter any treatment you are currently taking; speak to your own clinician about your care.
Related articles
Headlights got brighter. The government has now written down what to do about it
On 23 October 2026 the Department for Transport published new guidance called "Minimising headlight glare and its effects". It does not create a new law. It pu…
Web and paper filing close in April 2028, and one rule has been paused
On 23 October 2026 Companies House published an update on how company accounts will have to be filed from April 2028. Two things changed, and they point in opp…
£621 million for AI, and up to £200 million in free model credits
On 24 October 2026 the Treasury set out the government's new plan for artificial intelligence. The Chancellor, John Healey MP, announced a package that the ind…